The effects of farnesyl:protein transferase inhibitors (FTIs) were evaluated against hormone-dependent and hormone-independent prostate cancer cell lines harboring mutant and wild type Ras. The combinations of the FTI with hormones and chemotherapy were explored. The effect of FTI on the growth of human prostate cancer lines was examined under anchorage-dependent and -independent conditions. Changes in Ras processing and cellular localization were examined by immunoblotting and immunocytochemistry. Hormonedependent (LNCaP) and -independent (TSU-Pr1, PC3 and DU145) human prostate cancer cell lines were growth-inhibited by the FTI L-744,832 at concentrations ranging from 100 nM to 20 mM. The inhibition was accompanied by loss of protein farnesylation and with the accumulation of Ha-Ras as its unprocessed, cytosolic form. No effect on N-and Ki-Ras processing was observed. The transformed phenotype of TSU-Pr1 cells, which possess a Ha-Ras Gly-12-Val activating mutation, reverted following FTI treatment. Enhanced antitumor effects were observed when the FTI was combined with gamma-radiation, etoposide, doxorubicin, cisplatin, estramustine and the antihormone bicalutamide. In particular, the combination of taxol and FTI was synergistic for DU145 cells, a cell line that is only marginally sensitive to the FTI alone. The sensitivity of human prostate cancer cell lines to the FTI is independent of the presence of mutations of tumor suppressors, cell cycle regulators and of the activation of a variety of oncogenes, including Ras. A cell line expressing mutated Ha-Ras is particularly sensitive. Enhanced antitumor effects were observed with an antiandrogen, g-irradiation, and several chemotherapeutic agents. These ®ndings support the clinical evaluation of FTIs alone or in combination as treatment for this disease. Prostate Cancer and Prostatic Diseases (2001) 4, 33±43.
Introduction
The response of prostate cancers to androgen ablation is among the most dramatic in clinical oncology. Unfortunately, they are rarely durable, and patients usually relapse with androgen-independent tumors. At that point, there is no standard therapy, but recent reports from several groups have shown that androgen-independent prostate cancers are not as resistant to therapy as previously believed. 1, 2 The result is a change in focus for clinical drug testing in this disease. No longer is the sole aim to ®nd new treatments and approaches, rather, there is also an effort to ®nd agents that enhance the effects of those compounds and therapies known to have signi®-cant antitumor effects, and to ®nd agents that might be useful prior to hormone treatment so as to minimize the toxicities associated with castration.
Farnesyltransferase inhibitors (FTIs) that block the ®rst and rate-limiting step in the post-translational processing of Ras represent one such drug. 3, 4 When ®rst evaluated, it was felt that these agents might be best suited for tumors harboring mutant Ras genes. In an earlier study, we showed, however, that these compounds inhibited the growth of human cancer lines, including prostate, in which Ras mutations are rarely found. 5, 6 Moreover, we found no correlation between the presence of activating Ras mutations and sensitivity to the drug. The results suggested that the blockade of other pathways might contribute to the antiproliferative effects of these agents.
The present study was undertaken to further examine the effects of FTIs on prostate cancer growth. We found that both anchorage-dependent and androgen-independent prostate cancer cell growth was sensitive to FTI and that the antiproliferative effect was accompanied by inhibition of wild type and mutant Ha-Ras processing, but not that of N-or Ki-Ras. In LNCaP and TSU-Pr1 cells, growth inhibition was associated with G1 arrest. However, only TSU-Pr1 cells, which harbor a Ha-Ras mutation, 7 underwent a morphologic reversion after FTI treatment, showing the differential role of Ras on controlling cell proliferation and morphology. Since FTI has been shown to be relatively non-toxic in animal models and phase I studies, it may be useful when given in combination with traditional cytotoxic treatments. We studied the effects of FTI in combination with other agents used to control prostate cancer cell growth. Additive effects were observed in combination with the anti-androgen bicalutamide, the chemotherapeutic agents doxorubicin, cisplatinum, etoposide, and estramustine, and g-radiation, and synergistic effects were observed with taxol. Furthermore, in an accompanying paper we demonstrate that the FTI suppressed the growth of TSU-Pr1, DU145 and PC3 cells as xenografts in nude mice. 8 These results support the evaluation of FTIs as monotherapy or in combination as a treatment for prostate cancer.
Materials and methods

Materials
FTI L-744,832 9 was kindly provided by Dr George Hartman (Merck & Co., West Point, PA). The drug was dissolved in phosphate buffered saline (PBS) to a ®nal concentration of 50 mM, and stocks were aliquoted and stored at À80 C. Estramustine was provided by Pharmacia, Sweden and dissolved in 100% ethanol. Bicalutamide (Casodex 1 ), a gift from Zeneca Pharmaceuticals, was dissolved in dimethylsulfoxide. Cisplatin, doxorubicin, etoposide and taxol were obtained from the Memorial Sloan-Kettering Pharmacy as ready-for-injection samples. Working stocks for taxol were made in dimethylsulfoxide.
Cell lines
The human prostate tumor cell lines LNCaP, DU145 and PC3 were obtained from the American Tissue Culture Collection. Dr David Nanus (MSKCC) provided TSU-Pr1 cells. Some of their molecular lesions are outlined in Table 1 . TSU-Pr1, DU145 and PC3 cells were grown in DMEXF12 (1X1) supplemented with 10% FBS, 2 mM glutamine and 50 units/ml each of streptomycin and penicillin. LNCaP cells were grown in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine and 50 units/ml each of streptomycin and penicillin. All cells were cultured at 37 C in a humidi®ed incubator with 5% CO 2 .
Cell proliferation and soft agar growth
Growth curves and soft agar colony formation assays were performed as previously described. 5 Brie¯y, cells were plated at 5000 to 10 000 cells per well on 6-well plates and treated with the FTI added from 1000-fold concentrated stocks in PBS. Equivalent volumes of PBS were added to control cultures. When untreated controls approached con¯uence, attached monolayers were trypsinized and cell number was determined using a Coulter counter. FTI's effect on anchorage-independent growth was assessed by plating cells in semi-solid agar, in the presence or absence of increasing FTI concentrations. Cells were layered as a 0.35% agar plug over a 0.7% agar bed and covered with 1 ml of media in 24-well plates. In drugtreated samples, both agar layers as well as the overlaying media contained drug. After 10 days, cultures were ®xed in 3% formaldehyde and colonies with a diameter greater than 100 mm were counted using an automatic colony counter. Both types of experiments were performed in triplicate.
Combinations
The following agents were used in combination with FTI: etoposide, estramustine, doxorubicin, cisplatin, bicalutamide and taxol. Cells were treated for 4 h with either vehicle or increasing drug concentrations. Monolayers were then washed with PBS and cultures were placed in full media supplemented or not with FTI at different concentrations. Cell number was determined after untreated controls approached con¯uence (6 ± 8 days). Bicalutamide was tested exclusively on LNCaP cells, as only this cell line is hormone-sensitive.
FTI in combination with g g-irradiation
DU145 cells were subjected to g-irradiation with a Gamma Cell 40 chamber containing two sources of 137 Cs (Atomic Energy of Canada). Cultures were either pretreated for 72 h with 20 mM FTI, treated post-irradiation or did not receive FTI. Cell number was determined when untreated, unirradiated controls approached con¯uence (6 ± 8 days). were concentrated by acetone precipitation and samples were analyzed via non-equilibrium pH two-dimensional gel electrophoresis as previously described. 10 Gels were ®xed, stained, destained, soaked in EN 3 HANCE (NEN) and exposed to X-ray ®lm for one month.
Ras-processing assays
We determined the effect of FTI on Ras processing by examining Ras subcellular localization and changes in electrophoretic mobility. For the subcellular fractionation assay, PC3 cells were grown in the presence or absence of FTI for 48 h. Cells were lysed in hypotonic buffer 10 and particulate and soluble fractions were separated by ultracentrifugation (100 000 g, 60 min). Proteins were concentrated by acetone precipitation and samples were analyzed by gel electrophoresis on a 12.5% gel. Ha-Ras was immunodetected with an anti-Ha-Ras monoclonal antibody (LA-069, Quality Biotech). To assay changes in mobility, cells were treated for 48 h with either 20 mM FTI or 15 mM lovastatin, or left untreated. Cells were lysed with RIPA buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% Na deoxycholate, 0.1% SDS, 10 mg/ ml each of soybean trypsin inhibitor, aprotinin and leupeptin and 1 mM phenylmethylsulfonyl¯uoride). Ras was immunoprecipitated with the pan-Ras Y13-259 monoclonal antibody bound to anti-rat IgG-agarose beads (Sigma) for 1 h at 4 C. Proteins were separated on a 12.5% SDSpolyacrylamide gel and each of the three Ras gene products was immunodetected with speci®c antibodies (Santa Cruz Biotechnology monoclonal antibodies sc-29, sc-31 and sc-30, for Ha, N and Ki-Ras, respectively). The manufacturer's reported speci®city for the three Ras antibodies was con®rmed in our laboratory with recombinant proteins and various cell lysates. Recombinant HaRas (Calbiochem) was run side-by-side with the cellular Ras samples, to indicate the position of unprocessed Ras. These antibodies were raised against nonconserved regions and did not exhibit crossreactivity among the three Ras gene products.
Immuno¯uorescence TSU-Pr1 cells were grown on ®bronectin-coated coverslips for 48 h in the presence or absence of FTI. Cells were ®xed with 100% methanol for 20 min at À20 C and blocked with 2% bovine serum albumin (BSA) in 0.05% Triton X-100/PBS for 30 min at 37 C. Slides were subsequently stained with speci®c monoclonal antibodies for Ha-Ras (anti-Ras LA-069, Quality Biotech) and tubulin a (clone 5B-152, Sigma) diluted in blocking buffer to 1X3000 and 1X1000, respectively. Following a 2 h incubation, slides were washed three times with 0.5% BSA in 0.05% Triton X-100/PBS and subsequently stained with secondary anti-mouse antibodies coupled to¯uorescein (Molecular Probes). DNA was stained with 3 mg/ml of bisbenzimide.
Flow cytometry
To collect cells for cell cycle analysis and apoptosis, cultures were seeded at a density of 2500 cells/cm 2 and incubated with or without FTI for increasing time periods. Cells¯oating in the media were collected by centrifugation and attached cells were removed by trypsinization. These populations were combined. Cell number was determined with a Coulter counter and viability was determined by the Trypan-blue exclusion assay. Aliquots containing over 300 000 cells were prepared for determination of cell cycle parameters and apoptosis. Nuclei were prepared according to, 11 stained with ethidium iodide and analyzed with a Becton Dickinson¯uorescence-activated cell sorter (FACS). Conversely, samples for whole cell¯ow analysis were stained with propidium iodide as previously described. 2 Dual label FACS analysis was employed to determine the effect of drug on DNA replication. 6 Thirty minutes before harvest, bromodeoxyuridine (BrdU) was added to the culture media to 10 mM. Cells were harvested as previous described and samples were ®xed and stained with anti-BrdU monoclonal antibodies conjugated with¯uorescein according to the manufacturer's conditions (Becton Dickinson). Total DNA was stained with propidium iodide.
Results
The FTI L-744,832 is 1000-times less effective in inhibiting the activity of the related geranylgeranyl:protein transferase I (GGPTase I). Figure 1 shows a dose-curve analysis for inhibition of anchorage-dependent growth by the FTI. The four human prostate cancer cell lines were inhibited at concentrations ranging from 100 nM to 20 mM (Table 1) . A ®fth cell line, Dupro-1, was also sensitive to the FTI. 5 The DU145 cell line was the most resistant, requiring 30-to 200-fold higher concentrations for inhibition. Colony formation in soft agar was also inhibited (Figure 2) , and the FTI concentrations required were comparable to those that inhibit growth on a solid support. Figure 3 shows that incubation of prostate cancer cells with FTI resulted in the effective inhibition of farnesylation of cellular proteins. As shown for PC3 cells, the FTI blocked the incorporation of radiolabeled mevalonate into proteins with Mr 43 to 70 kDa. A two-dimensional gel electrophoretic analysis of the 3 H-isoprenylated proteins demonstrates the disappearance of speci®c labeled spots in the FTI-treated sample (Figure 3) . The spots at 67 and 70 kDa, represent lamin B and the precursor of lamin A, 10 which accumulate in the unprocessed form in the presence of the inhibitor. 5, 13 Co-migration of geranylgeranylated Ras-like proteins with Ras obscures the effect of the FTI on Ras processing. Other changes are easier to observe (Mr 44 to 47 kDa), but the identity of the proteins in question is unknown Ð not all farnesylated proteins have been characterized.
We studied the effect of FTI on Ras processing by analyzing changes in mobility in polyacrylamide gel electrophoresis and in the subcellular distribution of Ras (by subcellular fractionation and immunohistochemistry). We ®rst explored the expression of each of the three Ras gene products in the four prostate cell lines. While the levels of N-and Ki-Ras were comparable among cell lines, the steady state levels of Ha-Ras varied widely (Figure 4 ).
The Ha-Ras mutated-TSU-Pr1 cells exhibited the highest levels of expression, followed by PC3, a cell line with wild type Ha-Ras. In contrast, LNCaP and DU145 cells expressed Ha-Ras to a degree barely detectable by immunoblotting. Changes in Ras processing can be detected by gel electrophoresis, as the unprocessed form migrates more slowly than fully processed Ras. While the prenylation inhibitor lovastatin inhibited processing of the three Figure 1 Human prostate cancer cell lines are sensitive to FTI. Cells lines were plated at 10 000 cells per well on 6-well plates and treated with increasing concentrations of FTI L-744,832. Drug was added from 1000 6 stock solutions dissolved in PBS. Control cultures received an equivalent volume of PBS. When untreated controls approached con¯uence, attached monolayers were trypsinized and cell number was determined using a Coulter counter. Experiments were repeated at least three times. Figure 2 FTI inhibits the anchorage-independent growth of human prostate cancer cells. Cells were grown in soft agar in the presence or absence of increasing FTI concentrations. Cells were layered as a 0.35% agar plug over a 0.7% agar layer and covered with 1 ml of media in 24-well plates. In drugtreated samples, both agar layers as well as the overlaying media contained drug. After 10 days, cultures were ®xed in 3% formaldehyde and colonies were counted using an automatic colony counter. Experiments were repeated at least three times.
Ras proteins, FTI only affected Ha-Ras (Figure 4) . No change in electrophoretic mobility was detected for Kiand N-Ras after FTI treatment.
We observed a dose-dependent accumulation of cytosolic Ha-Ras in FTI-treated cells which was consistent with inhibition of Ras farnesylation ( Figure 5 A ± C) . FTI induced the translocation of Ha-Ras from the plasma membrane to the cytosol as seen in confocal micrographs of TSU-Pr1 cells stained with a Ha-Ras antibody ( Figure 5  A and B) . This translocation was con®rmed by subcellular fractionation ( Figure 5C ). FTI induced the accumulation of Ha-Ras in the cytosolic (S100) fraction. The kinetics of inhibition of Ha-Ras processing was analyzed by following changes in electrophoretic mobility of Ha-Ras. In TSU-Pr1 cells, a 12 h incubation with 5 mM FTI resulted in 50% of Ha-Ras to be unprocessed, reaching 75 to 85% after 24 h ( Figure 5D ).
Treatment of TSU-Pr1 cells with FTI at concentrations equal or higher than 10 nM, induced cell¯attening and extensive cytoskeletal changes as observed by H-mevalonate (100 mCi/ml) in the presence or absence of the 20 mM FTI. Cells were lysed in hypotonic buffer, proteins were concentrated by acetone precipitation and samples were analyzed via non-equilibrium pH two-dimensional gel electrophoresis. Gels were ®xed, stained, soaked in EN 3 HANCE (NEN) and exposed to X-ray ®lm for one month. immuno¯uorescence for the microtubule network ( Figure 6 ). These changes were dose-and time-dependent, becoming evident as early as 12 h (data not shown), and correlated with the kinetics and dose requirements for inhibition of Ha-Ras processing ( Figure 5 ) and subcellular distribution (Figure 4) . The changes were not detected in any of the other cell lines, including PC3, a cell line with elevated steady-state levels of wild type Ha-Ras.
The morphologic changes observed in TSU-Pr1 cells ( Figure 6) were not secondary to growth arrest, as the TSU-Pr1, PC3 and LNCaP cells arrested in G1 in response to the FTI ( Figure 7A ). Flow cytometric studies revealed that growth inhibition was unrelated to changes in apoptotic ratios (data not shown), but involved inhibition of G1 to S progression (Figure 7 B and C) . FTI treatment markedly inhibited the incorporation of bromodeoxyuridine (BrdU) into newly synthesized DNA and cells accumulated in G1 at the expense of cells in S and G2/M.
The sensitivity of human prostate cancer cell lines to the FTI, and the minimal toxicities observed in animal Figure 5 Effects of FTI on Ha-Ras processing and subcellular localization. TSU-Pr1 cells were plated on ®bronectin-coated glass coverslips and grown /71 mM FTI for 48 h (A) untreated (B) FTI-treated. Slides were ®xed, blocked and Ha-Ras was immunodetected by incubation with anti-Ras LA-069 (Quality Biotech). Slides were subsequently stained with a secondary anti-mouse IgG coupled to¯uorescein (green). DNA was stained with bisbenzimide (blue). Slides were analyzed by confocal microscopy (C) PC3 cells were grown in the presence or absence of FTI for 48 h. Lysates were made in hypotonic buffer and particulate (P100) and soluble (S100) fractions were separated by ultracentrifugation. Proteins were analyzed by SDS-PAGE on a 12.5% gel. Ras was immunodetected with an anti-Ha-Ras monoclonal antibody (LA-069, Quality Biotech). (D) TSU-Pr1 cell cultures were either untreated or grown for either increasing time periods with 5 mM FTI. Ha-Ras was immunodetected by Western blotting on 12.5% polyacrylamide gels. The proportion of processed and unprocessed Ha-Ras was quantitated with a Bio Rad Image Analyzer. FTI in prostate cancer L Sepp-Lorenzino et al models stimulated our interest in studying the effects of FTI in combination with traditional hormonal therapy, cytotoxic drugs and gamma-radiation. The only hormone-responsive cell line of the set is LNCaP. These cells express a mutated androgen receptor, yet they remain sensitive to anti-hormone therapy. 14, 15 When FTI was given in combination with the antiandrogen bicalutamide, growth was inhibited in an additive fashion (Figure 8 ). Additivity and synergy were determined using the combination index-isobologram method of Chou and Talalay. 16 This method is based on the median-effect principle and takes into account not only the potencies of each drug singly or in combination, but the shapes of their dose ± effect curves. Additive effects were also observed using sensitive TSU-Pr1 cells and the marginally resistant DU145 cell line when the FTI was added to doxorubicin, cis-platinum, etoposide or estramustine, the effects of the FTI were additive (Figure 9 ). Of particular interest was the taxol-FTI combination which had additive growth inhibitory effects on TSU-Pr1 cells, and synergistic effects on DU145 cells, a cell line moderately resistant to both drugs ( Figure 9 ). Additive effects were also observed with g-radiation, regardless of whether cells received FTI prior to, during or after irradiation ( Figure 10 ).
Discussion
Evidence indicates that Ras may play a role in prostatic tumor progression from an androgen-dependent intraprostatic lesion to androgen-independent disease. Introduction of an activated Ha-ras oncogene into hormone-dependent LNCaP cells confers hormone independence, 17 an increase in the number of ras mutations (in Ha-and Ki-ras) was detected during progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T-antigen transgenic, 18 and activation of growth factor pathways that operate through the tyrosine kinase receptor b Ras b Raf b MAPK pathway have been shown to become operational in advanced hormone-independent prostate tumors. 19 Moreover, expression of the dominant negative Ha-ras N116Y mutant 20 or of the Krev-1 ras-suppressor gene 21 into human tumor prostate cell lines, inhibited transformation in vitro and reduced tumorigenicity in vivo. Activated ras mutations rarely occur in American patients but a signi®cant number of Japanese patients have mutations in Ha-ras (24% of tumors, 68% in Ha-ras). 22 ± 28 Therefore, functional activation of ras, rather than mutational activation, might play a crucial role in prostate tumor development in Western countries, whereas ras mutation seem to be a contributing factor for tumorigenesis in the East. FTI inhibition of ras processing could therefore be a useful strategy for the treatment of advanced prostate cancer.
The carboxy terminus of Ras undergoes extensive modi®cation. Farnesylation of a Cys residue in the CAAX box, removal of the terminal tripeptide and carboxymethylation of C-terminus, renders this domain highly hydrophobic and ensures its partitioning to the plasma membrane. 29 By impeding its subcellular localization, treatment with FTIs brands Ras biologically inactive. The present study provides a rationale for the evaluation of FTI in human prostate cancer. 22, 23, 27 Three established human prostate cell lines with wild-type Ras, 7, 26 including the hormone-dependent LNCaP line, 14,15 the hormone-refractory, p53 and Rb-de®cient DU145 line, 30, 31 and the mutant p53 with wild type Rb PC-3 cells, 31, 32 proved sensitive to these agents in vitro, and in human prostate xenograft models in nude mice. 8 One additional cell line, TSU-Pr1 cells, 33 which harbors Ha-ras Gly-12-Val mutation 7 showed both growth inhibition and reversion of the transformed phenotype.
We found that FTI was active towards hormone-dependent as well as against refractory tumors, corroborating our previous observation that sensitivity was independent of ras mutations and of various genetic abnormalities associated with tumor development, such as Rb loss and mutation of p53. 5 Cell growth inhibition was not due to increased cell death but to cell cycle arrest (Figure 7) . The FTI induced G1 arrest in LNCaP, PC3 and TSU-Pr1 cells and progression through the S phase was severely impaired. DU145 cells are marginally growth inhibited by the FTI, and no apparent cell cycle changes were detected (data not shown). Increasing evidence indicates that the effect of prenylation inhibitors on cell cycle dynamics are complex and vary from cell line to cell line. 6,34 ± 36 In particular, we have found that FTI induces a p53-dependent induction of p21, which results in G1 arrest. 6 The current results further increase the complexity of the mechanism by which FTI inhibits cell growth. PC3 and TSU-Pr1 cells arrested in G1 in response to the FTI despite having mutated p53.
The effects of the FTI on Ras processing raise the question of whether Ras is central for the FTI effect. HaRas processing was effectively blocked by the FTI, but no effect on N-or Ki-Ras was observed (Figures 4 and 5) . Previous work has shown that Ki-Ras becomes geranylgeranylated in the presence of FTI and thus remains in the plasma membrane. 37 ± 40 Here we expand these observations and show that these cells are sensitive to the growth effects of the drug. These results could be explained in several ways, of which one is that Ras is not the critical target for growth control. Alternatively, the three ras gene products might have separate functions, and Ha-Ras expression may be necessary for cellular proliferation. Lastly, geranylgeranylation of N-and Ki-Ras might affect their function, so that their ability to transduce the growth signal is compromised. In this regard, each of the prostate cancer cell lines studied expresses different basal levels of each of the Ras proteins ( Figure 5B ). Thus, some of the pleiotropic effects of the FTI may be explained by the relative abundance of FTI-sensitive (Ha-) and-resistant (N-and Ki-) Ras proteins.
Cells driven by mutant Ha-Ras, such as TSU-Pr1, appear to be uniquely sensitive to the drug in terms of growth and morphology (Figures 1 and 6 ). These effects have already been seen in other tumor cell lines and in ®broblasts transfected with mutationally-activated Ras genes. 37,41 ± 44 Morphologic reversion of TSU-Pr1 cells was unrelated to growth inhibition and G1 arrest induced by FTI, as treatment with other agents that cause a cell cycle block did not result in morphologic changes (data not shown). In addition, inhibition of wild type Ha-Ras processing as observed on PC3 cells which express high basal levels of wild type Ha-Ras, did not result in a morphologic reversion. In other systems, FTIs not only inhibited the oncogenic potential of v-Ha-Ras, in vitro and in vivo, but caused regression of established tumors. 41, 45, 46 Sensitivity to the FTI is therefore not dependent on the presence of Ras mutation or the unprocessing of wild type Ras in response to drug treatment. The data suggest that FTI affects the processing of other targets that are important for tumor growth or that our current model of Ras function is incomplete. 44, 47, 48 In this regard, it is important to remember that FTIs are farnesylation inhibitors and that there are other cellular proteins besides Ras that are subjected to this type of post-translational modi®cation. As shown in Figure 3 , FTI treatment inhibits the farnesylation of several proteins whose identities are unknown. For example, little is known about the doublet at 43 ± 47 kDa, beyond its partitioning to the nuclear matrix-intermediate ®lament compartment. 10 Further, many farnesylated proteins are being identi®ed by expression cloning and by the two-hybrid system, increasing the probability of identifying the complete complement of farnesylated proteins in the near future. Candidates that could ful®ll this role are a family of protein tyrosine phosphatases (PRL1) with oncogenic properties, an inositol phosphatase and members of the Ras-like superfamily, like RhoB, RhoE, Rheb. In fact, Prendergast and others have proposed that RhoB might be the target responsible for changes in morphologic transformation induced by the FTI 43, 44, 47, 48 as was observed in TSU-Pr1 cells.
Several FTIs are now undergoing phase I clinical trial and preliminary results show the agents to be safe and well-tolerated making them ideal agents to explore in combination. The original conception was that these drugs would ®nd their most appropriate use in tumors with mutations in the ras gene. Furthermore, despite the profound regressions produced by the drug in some animal models, 45, 46 the drug usually results in stable disease in this type of system. This has led to the supposition that the drug will have to be given chronically in order to be of any use.
Our work and that of others calls these assumptions into question. As described above, FTIs probably affect tumor cell growth by preventing the farnesylation of multiple targets only a few of which have been identi®ed (Ras, RhoB.) The critical target in a particular tumor and the consequences of inhibition of that target may vary as a function of the other mutations present in that tumor. These results suggest caution should be exercised in making presumptions about the optimal clinical strategies. As shown here, tumors with wild type Ras are prime candidates for FTI therapy. It is not clear whether the drug will be static or induce apoptosis in such tumors. The pattern of ras gene expression and the p53 status of the tumor may, in part, determine the nature of the response. Therefore, although the drug will have to be present long enough to result in the unprocessing of the critical target, it is not certain that it will have to be present in all tumors. Furthermore, FTIs may be useful agents when given in combination with chemotherapy, radiation therapy or antiandrogens. When used in combination therapy, FTI may enhance the cytotoxic effects of drugs; in this case chronic long-term administration would not be required for ef®cacy.
Our data suggest that prostate cancer cells are growthinhibited by a variety of mechanisms in response to FTI. It could be useful as a single agent or in combination with hormonal, radiation, or chemotherapy in the setting of locally advanced or disseminated hormone-independent prostate cancer.
